Euratom: Where Are We Now?
Hamid Yunis, partner and head of healthcare at the London office of international law firm, McDermott Will & Emery, discusses the potential negative impact of Brexit and the UK leaving…
Address: 16 John Street, London WC1N 2DL
Tel: +44 (0)20 7421 7400
Web: http://www.specialityeuropeanpharma.com/
Speciality European Pharma was founded in 2006 to acquire, develop, register and commercialise speciality therapeutic products for the expanding European market, with a strong focus on urology.
The company is dedicated to improving the range of products available in Europe to treat urological diseases, including the urological cancers.
Plenaxis® is the company’s lead product. It is a hormonal products to treat advanced and metastatic prostate cancer.
Mitem® is used in the treatment of a range of cancers.
Regurin® is used to treat the symptoms of overactive bladder
Haemopressin® is a critical care product for the treatment of bleeding oesophageal varices.
Hamid Yunis, partner and head of healthcare at the London office of international law firm, McDermott Will & Emery, discusses the potential negative impact of Brexit and the UK leaving…
Among the assorted pharma CEOs and KOLs gathered at the recent Financial Times Pharmaceutical and Biotechnology Conference in London, debate raged on the pros and cons of a pure play strategy, focusing…
In an exclusive interview at the eyeforpharma Barcelona Summit 2016, Janssen EMEA’s Jane Griffiths speaks out about patient-centricity, sustainability and the dawning of a new world of healthcare. What’s been keeping you…
In an exclusive interview at the eyeforpharma Barcelona Summit 2016, GSK’s Danie Du Plessis speaks out about patient-centricity and the growing role of medical affairs in the pharma industry. In your…
Can you provide us with an overview of what the UK market represents for the greater Lonza group? Lonza Biologics is a contract manufacturing organisation employing approximately 650 people in…
Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have for the company? When…
As the head of Eisai’s European operations, how would you assess the relevance of the European market for Eisai’s global operations when compared to the US or emerging markets? Gary…
Following the acquisition of Arrow Generics by Watson in December 2009, what complementarities and synergies were generated from the transaction and where do you stand today with the integration? Since…
As a partner at Apposite since the company was created in 2006, what was the founding vision of the company and what do you consider have been its major milestones…
Apitope’s research and success is based on its High Speed Technology Platform that uses soluble peptides as vehicles to regulate immune responses in patients. What is the history behind this…
As the global economic roller coaster continues to unfold, governments the world over have desperately been scrambling to find the right policies that will effectively clamp on the brakes to…
Given the global trend of clinical research increasingly being outsourced to emerging markets, such as Asia and Latin America, where does this leave historical hubs of clinical research such as…
See our Cookie Privacy Policy Here